Synthesis of Coumestrol and Coumestans
(95%): 1H NMR (CDCl3) δ 2.21 (s, 3H), 7.25 (dd, J ) 8.1, 1.2
Hz, 1H), 7.32-7.40 (m, 3H), 7.44-7.53 (m, 3H), 7.82 (dd, J )
7.8, 1.8 Hz, 1H); 13C NMR (CDCl3) δ 21.3, 65.4, 111.4, 122.1,
123.3, 123.7, 123.8, 126.0, 126.1, 131.2, 131.7, 131.9, 148.8,
152.3, 154.6, 169.4; IR (neat) 1771 cm-1; HRMS calcd for
C16H11IO3 377.9758, found 377.9753.
General Procedure for Palladium-Catalyzed Intra-
molecular Lactonization. DMF (1.0 mL), PdCl2(PPh3)2
(0.0125 mmol), K2CO3 (0.5 mmol), and the aryl iodide (0.25
mmol) were stirred under an Ar atmosphere at room temper-
ature for 5 min. The mixture was flushed with CO, and the
flask was fitted with a balloon of CO. The reaction mixture
was heated at the specified temperature with vigorous stirring
for 6 h. The reaction mixture was then cooled to room
temperature, diluted with diethyl ether (35 mL), and washed
with brine (30 mL). The aqueous layer was extracted with
diethyl ether (15 mL). The organic layers were combined, dried
over anhydrous Na2SO4, and filtered, and the solvent was
removed under reduced pressure. The residue was purified by
column chromatography on a silica gel column.
Coumestan (2). This compound was obtained as a white
solid (99%): mp 180-181 °C (lit.21 mp 181-182 °C); 1H NMR
(CDCl3) δ 7.39-7.53 (m, 4H), 7.59-7.69 (m, 2H), 8.04 (dd, J
) 7.8, 1.5 Hz, 1H), 8.13-8.16 (m, 1H); 13C NMR (CDCl3) δ
106.1, 112.0, 112.9, 117.7, 122.1, 123.7, 124.9, 125.4, 127.0,
132.1, 153.9, 155.8, 158.3, 160.2; IR (neat) 1737 cm-1; HRMS
calcd for C15H8O3 236.0476, found 236.0473. The spectral
properties were identical to those previously reported.21
Plicadin (29). Compound 28 was converted to the structure
originally proposed for plicadin (29) by following the same
procedure used to prepare lactone 21. This afforded the
proposed plicadin (94%) as a yellow solid: mp 290-291 °C
(sublim). The spectral properties were identical to those
previously reported.20
1
deprotection with TBAF. The H NMR spectrum of our
synthesized plicadin is identical to that of Snieckus’
plicadin.20 Although it does not establish the correct
structure of plicadin, our iodocyclization/carbonylation
methodology should provide direct access to a large
number of biologically interesting coumestan derivatives.
In summary, we have developed an efficient approach
to biologically interesting coumestans that involves simple,
high-yielding Sonogashira cross-coupling, iodocyclization,
and Pd-catalyzed lactonization using an acetoxy group
as the nucleophile. A variety of biaryls can be utilized in
this process to generate aromatic lactones in good yields.
More importantly, the methodology we have developed
can be applied to the synthesis of coumestan, coumestrol,
plicadin, other coumestan family members, and a wide
variety of coumestan analogues.
Experimental Section
General Procedure for the Sonogashira Cross-Cou-
pling: 2-(2-Methoxyphenylethynyl)phenyl Acetate. A
mixture of 2-ethynylanisole (6.0 mmol), 2-iodophenyl acetate
(5.0 mmol), CuI (0.06 mmol), and PdCl2(PPh3)2 (0.12 mmol) in
a mixture of Et3N (2.0 equiv) and DMF (50 mL) was heated
at 60 °C for 2 h. The precipitate was filtered off, and the filtrate
was concentrated under reduced pressure. The residue was
extracted with Et2O, and the combined extracts were washed
successively with water and satd aq NaCl. The organic solution
was dried over anhydrous Na2SO4 and evaporated. The residue
was purified by flash chromatography on silica gel (4:1 hexane/
EtOAc) to give the above product (96%) as a yellow oil: 1H
NMR (CDCl3) δ 2.37 (s, 3H), 3.87 (s, 3H), 6.88 (d, J ) 8.7 Hz,
1H), 6.92 (td, J ) 7.5, 0.9 Hz, 1H), 7.11 (dd, J ) 8.1, 1.5 Hz,
1H), 7.20 (td, J ) 7.5, 1.5 Hz, 1H), 7.26-7.35 (m, 2H), 7.46
(dd, J ) 7.5, 1.8 Hz, 1H), 7.59 (dd, J ) 7.5, 1.8 Hz, 1H); 13C
NMR (CDCl3) δ 21.0, 55.8, 88.3, 90.9, 110.9, 112.3, 118.0, 120.6,
122.4, 126.0, 129.4, 130.2, 133.1, 133.7, 151.6, 160.1, 169.1;
IR (neat) 1771 cm-1; HRMS calcd for C17H14O3 266.0946, found
266.0943.
General Procedure for Iodocyclization: 2-(2-Acetoxy-
phenyl)-3-iodobenzo[b]furan (1). This compound was pre-
pared according to a literature procedure.8 A solution of 2-(2-
methoxyphenylethynyl)phenyl acetate (2.50 mmol) in dry
CH2Cl2 (10 mL) was stirred at room temperature for 1 min. I2
(2.5 equiv) was added, and the resulting mixture was allowed
to stir at 25 °C for 12 h. Satd aq Na2S2O3 (5 mL) was added to
the mixture, which was further stirred for 2 min. The resulting
mixture was then extracted with Et2O. The combined organic
solution was washed successively with water and satd aq
NaCl, dried over anhydrous Na2SO4, and concentrated under
vacuum. The residue was purified by flash chromatography
on silica gel (4:1 hexane/EtOAc) to afford 1 as a yellow oil
Acknowledgment. We gratefully acknowledge the
University of Kansas Chemical Methodologies and
Library Development Center of Excellence (NIH P50
GM069663), and the National Institutes of General
Medical Sciences and the National Institute of General
Medical Science (GM070620) for financial support of this
work, and Johnson Matthey, Inc., and Kawaken Fine
Chemicals Co., Ltd., for donations of palladium cata-
lysts.
Supporting Information Available: Characterization
data for the compounds listed in Table 1 and experimental
procedures and characterization data for the reactions sum-
marized in Schemes 3 and 4. This material is available free of
JO0517038
(21) Larock, R. C.; Harrison, L. W. J. Am. Chem. Soc. 1984, 106,
4218.
J. Org. Chem, Vol. 70, No. 24, 2005 9989